Table 3.
Characteristics of 12 patients with HBV infection and Advanced-Stage Cancer included in the FDA Adverse Event Reporting System
| Patient | Age | Gender | Country | Cancer Type | ICIs | Combined treatment | Outcome | Received Date | Response |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 71 | M | USA | Malignant Melanoma Stage Iv | Pembrolizumab | No | Other | 20-Apr-19 | - |
| 2 | Not Specified | F | USA | Neoplasm Malignant | Pembrolizumab | No | Other | 7-Jun-17 | - |
| 3 | 36 | F | France | Non-Hodgkin'S Lymphoma | Pembrolizumab | Adcetris | Other | 11-Sep-18 | - |
| 4 | 57 | M | Bulgaria | Non-Small Cell Lung Cancer Metastatic | Pembrolizumab | Methylprednisolone | Died | 22-Apr-19 | PR |
| 5 | Not Specified | M | Bulgaria | Small Cell Lung Cancer | Pembrolizumab | No | Other | 26-Feb-19 | PD |
| 6 | Not Specified | Not Specified | USA | - | Pembrolizumab | No | Other | 22-Mar-16 | - |
| 7 | 45 | M | Korea | Hepatocellular Carcinoma | Nivolumab | No | Died | 19-Jan-18 | PD |
| 8 | Not Specified | Not Specified | Japan | Malignant Melanoma | Nivolumab | No | Other | 14-Dec-15 | - |
| 9 | Not Specified | Not Specified | USA | Hodgkin'S Lymphoma | Nivolumab | Rituximab etc | Died | 23-Jan-19 | - |
| 10 | Not Specified | M | HK | Transitional Cell Carcinoma | Atezolizumab | No | Other | 30-Mar-18 | - |
| 11 | 83 | F | Belgium | Triple Negative Breast Cancer | Atezolizumab | Paclitaxel | Other | 15-Jun-20 | - |
| 12 | 67 | M | France | Lung Adenocarcinoma | Durvalumab | No | Died | 18-Nov-19 | - |